Sigyn Therapeutics (SIGY) EBT Margin (2017 - 2020)
Sigyn Therapeutics (SIGY) posted EBT Margin of 7720.14% for Q3 2020, up 76.76% sequentially from 33225.13% in Q1 2020, and down 728844.0% YoY from N/an in Q4 2019.
Sigyn Therapeutics (SIGY) EBT Margin (2017 - 2020) Analysis & Trends
Sigyn Therapeutics has reported EBT Margin for 4 years, with the latest figure at 7720.14% in Q3 2020.
- Quarterly EBT Margin fell 728844.0% year-over-year to 7720.14% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 8149.04% (down 695234.0% YoY) and the FY2019 annual result came in at 2311.58%, up 581766.0% from the prior year.
- EBT Margin advanced to 7720.14% in Q3 2020 per SIGY's latest filing, from 33225.13% in the prior quarter.
- Over five years, EBT Margin peaked at 121147800.0% in Q4 2018 and troughed at 33225.13% in Q1 2020.
- A 4-year average of 8649940.8% and a median of 401.55% in 2018 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2018 and 2019: EBT Margin jumped 2000000000 bps in 2018, then tumbled 2000000000 bps in 2019.
- Over 4 years, EBT Margin stood at 83.34% in 2017, then surged by 145359446 bps to 121147800.0% in 2018, then slumped by 100 bps to 29.03% in 2019, then slumped by 26492 bps to 7720.14% in 2020.
- According to Business Quant data, EBT Margin over the past three periods registered 7720.14%, 33225.13%, and 29.03% for Q3 2020, Q1 2020, and Q4 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 12.09% |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -7,720.14% |
| Mar 31, 2020 | -33,225.13% |
| Dec 31, 2019 | -29.03% |
| Sep 30, 2019 | -431.70% |
| Jun 30, 2019 | -181.59% |
| Mar 31, 2019 | -443.65% |
| Dec 31, 2018 | 121,147,800.00% |
| Sep 30, 2018 | -371.39% |
| Jun 30, 2018 | -2,627.69% |
| Mar 31, 2018 | -2,644.79% |
| Dec 31, 2017 | 83.34% |
| Sep 30, 2017 | -585.10% |
| Jun 30, 2017 | -223.68% |
| Mar 31, 2017 | -228.28% |